The Nobel Chronicles

  title={The Nobel Chronicles},
  author={Tonse N K Raju},
  journal={The Lancet},
  • T. Raju
  • Published 18 September 1999
  • Philosophy
  • The Lancet

Dysbiosis From a Microbial and Host Perspective Relative to Oral Health and Disease

This review will emphasize the role that commensals and pathobionts play in their interaction with the immune status of the host, with a prediction that current “omic” technologies will allow researchers to better understand disease in the future.

Immunotherapy for Pediatric Sarcomas

Early results from several trials indicate that this powerful strategy will eventually bear fruit, adding to the multimodal armament needed to cure high-risk malignancies.

Monoclonal Gammopathies of Renal Significance: Renal Biopsy and Beyond

The present review deals with the implications of MGRS for renal function and prognosis, and the potential of tools, such as the renal biopsy, for assessing clinical risk and guiding therapy of the underlying condition.

The Role of Organic Synthesis in the Emergence and Development of Antibody-Drug Conjugates as Targeted Cancer Therapies.

This Review is primarily focusing on the chemical synthesis aspects of the ADCs multidisciplinary research enterprise, covering oncological applications and a brief history of the emergence of the field of antibody-drug conjugates triggered more than a century ago by Paul Ehrlich's "magic bullet" concept.

Immunomodulatory Functions of the Gastrointestinal Tract

This chapter is concerned with structure–function relationship of the lymphoid tissues of the GI tract and associated pathological conditions and the molecular mechanisms of functioning of GALT in normal and diseases are discussed.

Prologue: The Term “Immunity” over the Course of Time

The long way of the term “immunity” is briefly sketched, ranging from its first registered use in the context of health and disease 2000 years ago up to the description of the self/nonself discrimination theory in immunology in the mid-1990s.

Mechanisms of monoclonal antibody-drug interactions.

The concept of monoclonal antibodies as pharmacotherapeutics was validated in the mid-1980s with the successful clinical development of the fully murine mAb muromonab-CD3 for prevention of acute organ rejection, but clinical applications are restricted, owing to the high incidence of serious immune-mediated side effects.